Dr. Clay Siegall runs Seattle Genetics, a company based in Seattle that deals with cancer research regarding drugs and therapies development. He has grown his business from a small company with few researchers to a great empire that commands respect in the field of Oncology. He has led his company in developing its first ADC, which is FDA-approved and over 20 cancer drugs as well as obtaining strategic partnerships with big drugs manufacturers. He is dedicated to creating new and better cancer treatments.
How Dr. Clay did it
Dr. Clay was fascinated with medicine and restoring health as well as the ability that comes with technology, but his interest in cancer came when one of his loved ones was diagnosed with cancer. The treatments that he received were not effective, which made him start looking into other options. His desire to see a change in treatment methods led him to start Seattle Genetics. The firm has been able to make money through selling its Adcetris drugs, partnerships, and licensing their drug technologies and processes. With the help of biotech experienced sales representatives, Dr. Clay was able to get his first batch of clients. The unique nature of the products has always created repeat customers. The firm took ten years to be profitable, which made Clay get some doubts, but he was able to pull through due to hard work and dedication. Dr. Clay has managed to remain successful through hard work, passion, and staying focused.
About Clay Siegall
Dr. Clay Siegall studied zoology and genetics at the highly ranked University of Maryland and the famed George Washington University respectively. After completing his college studies, he worked for the National Institutes of Health for three years until 1991 before joining Bristol-Myers Squibb Institute where he worked as a senior researcher. He left in 1997 and started Seattle Genetics the following year.
Dr. Clay Siegall has always been productive in his works, which has made him an award winner. He scooped Alumnus of the Year for Computer, Math, and Natural Sciences issued by the 2013 University of Maryland and the Young Executive of the Year in 2012.